- Home
- GPGI vs KNSA Comparison
GPGI vs KNSA Comparison
Compare GPGI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$76.28
Company Overview
Basic Information| Metric | GPGI | KNSA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United Kingdom |
| Employees | 977 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GPGI | KNSA |
|---|---|---|
| Price | $15.51 | $76.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.3M | 771.4K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $768.10 | $37.48 |
| Revenue Next Year | $126.25 | $17.87 |
| P/E Ratio | ★ N/A | $271.89 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $11.22 | $31.78 |
| 52 Week High | $25.66 | $82.94 |
Technical Indicators
Market Signals| Indicator | GPGI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 62.35 |
| Support Level | $14.11 | $39.42 |
| Resistance Level | $17.50 | N/A |
| Average True Range (ATR) | 0.75 | 3.57 |
| MACD | -0.02 | 0.68 |
| Stochastic Oscillator | 97.80 | 58.25 |
Price Performance
Historical Comparison GPGI
KNSA
About GPGI GPGI Inc.
GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.